INCIVO

Type: Product

Name: INCIVO

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Triple therapy for hepatitis C is effective after liver transplantation, but side-effects are common

Adding the approved HCV protease inhibitortelaprevir (Incivo or Incivek) to pegylated interferon andribavirin can increase sustained viral response rates even for difficult-to-treatliver transplant recipients, but adverse events are common, researchers ... [Published Aidsmap - May 16 2013]

Entities: Hepatitis C, INCIVO, INCIVEK, Telaprevir, protease inhibitor

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Decision Resources Brings Out Emerging Markets Physician & Payer Forum Report

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, announced that it found that the majority of hepatitis C virus (HCV) patients in Brazil, Mexico and Argentina rely entirely on government-sponsored medical programs ... [Published Individual.com - May 16 2013]

Entities: Decision Resources Group, Physician, Protease, VICTRELIS

First reported May 13 2013 - Updated May 13 2013 - 1 reports

In Brazil, Mexico and Argentina, Dual Combination Therapy With Peg-IFN-alpha and Ribavirin Remains the Most Commonly Pre

/PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of hepatitis C virus (HCV) patients in Brazil, Mexico and Argentina rely entirely on government-sponsored ... [Published NewsBlaze - May 13 2013]

Entities: ribavirin, Mexico, Argentina, Brazil, Patient

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Motley Fool

Johnson & Johnson Stock Is on the Mend

Filed under: InvestingJohnson & Johnson stock is turning around in a big way.After seeing revenue decline two years in a row , the company posted two years of revenue growth, and first-quarter revenue was up a solid 8.5%.Investors are convinced this isn't ... [Published Daily Finance - May 09 2013]

Entities: Johnson & Johnson, Motley Fool, Vertex Pharmaceuticals Inc

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Johnson & Johnson

Johnson & Johnson (JNJ), Pfizer Inc. (PFE): Take Two Dividend Stocks and Call Me in the Morning

Dividend stocks can be a great addition to your portfolio, especially pharmaceutical dividend stocks that offer a bit of stability in rocky times. People still get sick during recessions.And the dividend allows investors to be patient, collecting the ... [Published InsiderMonkey.com - May 01 2013]

Entities: Johnson & Johnson, Dividend, Pfizer Inc

First reported May 01 2013 - Updated May 01 2013 - 2 reports

Vertex Pharmaceuticals Inc

Vertex Loss Lower, Kalydeco Outlook Up - Analyst Blog

Vertex Pharmaceuticals Inc. (VRTX) posted a loss of 12 cents per share (including stock-based compensation expense) in the first quarter of 2013, well below the year-ago earnings of 41 cents per share. First quarter 2013 loss was, however, narrower than ... [Published Quote.com India - May 01 2013]

Entities: Vertex Pharmaceuticals Inc, INCIVEK, INCIVO, Johnson & Johnson, Research & Development

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care

An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previouslytreated hepatitis C (HCV) patients who did not respond to interferon-based tripletherapy using the approved HCV protease inhibitors boceprevir (Victrelis) ... [Published Aidsmap - Apr 29 2013]

Entities: Sofosbuvir, Hepatitis C, INCIVO, Boceprevir, VICTRELIS

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Incivo® receives positive opinion

Janssen Infectious Diseases-Diagnostics BVBA (Janssen), has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of twice daily (BID) dosing ... [Published Hospital Pharmacy Europe - Apr 29 2013]

Entities: INCIVO, Telaprevir, European Medicines Agency, Hepatitis C

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

J&J’s prescription, OTC drugs sales rise in Q1

NEW YORK: Johnson & Johnson (J&J) beat Wall Street’s quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter (OTC) medicines that had been recalled over quality control problems.Newer prescription ... [Published The Gulf Today - Apr 22 2013]

Entities: Johnson & Johnson, nonprescription, Drugs, Motrin, Tylenol

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Johnson & Johnson net dips by 10.6% to $3.5 bn in Q1

Johnson & Johnson (J&J) has suffered a setback during the first quarter ended March 2013 on account of provision for litigation expenses and integration and transaction costs related to the acquisition of Synthes Inc. Its net earnings declined by 10.6 ... [Published PharmaBiz - Apr 19 2013]

Entities: Johnson & Johnson, Synthes Inc, Invega Sustenna, INCIVO

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

J&J Q1 tops on new drug Investor's Business Daily

The medical giant said EPS rose 5% to $1.44, beating views by 4 cents. Sales rose 8.5% to $1.45 bil, slightly above analyst estimates. Johnson & Johnson's (JNJ) drug sales climbed more than 11% on the debut of the anticoagulant Xarelto, prostate-cancer ... [Published Yahoo! Finance - Apr 17 2013]

Entities: Johnson & Johnson, Drugs, INCIVO, Xarelto

First reported Apr 16 2013 - Updated Apr 17 2013 - 4 reports

J&J tops estimates as prescription,

By Ransdell Pierson(Reuters) - Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicines that had been recalled over quality control problems ... [Published Yahoo! UK and Ireland - Apr 16 2013]

Entities: Johnson & Johnson, Rick Wise, Stelara, nonprescription, Motrin

Quotes

...capabilities, Janssen expects to continue to make significant contributions to global human health and deliver strong business results," Duato said. "Our number one priority is to build upon our strong momentum with the goal of transforming patients' lives well into the future."

J&J's Janssen Poised to Continue Driving Growth, Outlines 10+ Potential New Product Filings by 2017 [Published Benzinga.com - 15 mins ago]

"[Simeprevir] was generally safe and well-tolerated," they added. "Shortened therapy duration in [simeprevir]-treated patients led to reduced fatigue severity and a more rapid return to normal activities."

DDW 2013: Simeprevir Boosts Response to Interferon-based Therapy for Prior Relapsers [Published HIV and Hepatitis.com - 16 hours ago]

"As in patients with cirrhosis, immediate therapy against HCV is warranted for patients with pre-cirrhosis and HIV coinfection, as they are at risk of liver decompensations soon after the diagnosis of advanced fibrosis" the investigators advised

EASL 2013: HIV/HCV Coinfected at Risk for Decompensation, May Need Prompt Treatment [Published HIV and Hepatitis.com - 20 hours ago]

...inhibitors in public programs in all three countries are currently gaining momentum," said Decision Resources Analyst Andreia Ribeiro, Ph D "In Brazil, Incivo and Victrelis are now being incorporated in public reference hospitals and state HCV programs, after a positive recommendation by Conitec (the national HTA body) for the inclusion of protease inhibitors in the National Health System in July, 2012. In Argentina, the Superintendencia de Servicios de Salud recently included protease inhibitors in the coverage of the Single Refund System. Therefore, the different SS funds (Obras Sociales) can now be reimbursed for the provision of triple therapy treatment to HCV1 patients. Additionally, in Mexico, the fact that Victrelis was recently included in the national formularies may lead to the incorporation of this drug in the SS sector soon."

Decision Resources Brings Out Emerging Markets Physician & Payer Forum Report [Published Individual.com - May 16 2013]

More Content

sort by: Date \| Relevance
J&J's Janssen Poised to Continue Driving Growth... [Published Benzinga.com - 15 mins ago]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published PR Newswire - 26 mins ago]
Johnson & Johnson Pharmaceuticals Segment Poise... [Published FinanzNachrichten.de - 28 mins ago]
DDW 2013: Simeprevir Boosts Response to Interfe... [Published HIV and Hepatitis.com - 16 hours ago]
EASL 2013: HIV/HCV Coinfected at Risk for Decom... [Published HIV and Hepatitis.com - 20 hours ago]
Triple therapy for hepatitis C is effective aft... [Published Aidsmap - May 16 2013]
Decision Resources Brings Out Emerging Markets ... [Published Individual.com - May 16 2013]
EASL 2013: Direct-acting Antivirals Boost Respo... [Published HIV and Hepatitis.com - May 14 2013]
Johnson & Johnson: An Investment In A Healthcar... [Published Seeking Alpha - May 13 2013]
In Brazil, Mexico and Argentina, Dual Combinati... [Published NewsBlaze - May 13 2013]
EASL 2013: Triple Therapy for Hepatitis C Is Ef... [Published HIV and Hepatitis.com - May 10 2013]
Johnson & Johnson Stock Is on the Mend [Published Daily Finance - May 09 2013]
EASL 2013: Vaniprevir Boosts Interferon/Ribavir... [Published HIV and Hepatitis.com - May 08 2013]
Gay men and access to HIV services [Published Aidsmap - May 08 2013]
Atripla Label Adds Drug Interactions with Hepat... [Published HIV and Hepatitis.com - May 05 2013]
EASL 2013: International Liver Congress Kicks O... [Published HIV and Hepatitis.com - May 04 2013]
EASL 2013: Compassionate Access to New Hepatiti... [Published HIV and Hepatitis.com - May 04 2013]
EASL 2013: HCV Protease Inhibitor Simeprevir Pu... [Published HIV and Hepatitis.com - May 03 2013]
EASL 2013: Sofosbuvir + Interferon/Ribavirin Cu... [Published HIV and Hepatitis.com - May 03 2013]
Shorter Treatments for Hepatitis C Patients on ... [Published Motley Fool - May 03 2013]
Report: All-Oral, IFN-Free Regimen Is Major Unm... [Published PT Community - May 03 2013]
In Treatment-Naive Hepatitis C Virus, Thought L... [Published NewsBlaze - May 02 2013]
Johnson & Johnson (JNJ), Pfizer Inc. (PFE): Tak... [Published InsiderMonkey.com - May 01 2013]
First Manhattan Files Preliminary Proxy Materia... [Published Daily Finance - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Equities.com - May 01 2013]
Vertex Loss Lower, Kalydeco Outlook Up - Analys... [Published Quote.com India - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Benzinga.com - May 01 2013]
VIVUS, INC.: First Manhattan Comments on Additi... [Published 4 Traders - May 01 2013]
First Manhattan Comments on Addition to Vivus' ... [Published Zecco - May 01 2013]
Vertex Loss Lower, Kalydeco Outlook Up Zacks [Published Yahoo! Finance - May 01 2013]

Blogs

sort by: Date \| Relevance
Johnson & Johnson Issues Weak Earnings Guidance... [Published Clusterstock - Jan 22 2013] Johnson & Johnson just reported earnings for the fourth quarter of 2012. The market is focused on the weak earnings guidance the company issued for 2013, in the range of $5.35-5.45 per share, below analysts' estimates of $5.49. Revenues in Q4 were ...

Press Releases

sort by: Date \| Relevance
Johnson & Johnson Pharmaceuticals Segment Poise... [Published PR Newswire - 26 mins ago]
INCIVO® Receives Positive Opinion from the Comm... [Published PR Newswire: Health - Apr 26 2013]